In vitro antiviral interaction of lopinavir with other protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 7, 2002, Pages 2249-2253

  Molla, Akhteruzzaman ^a   Mo, Hongmei ^a   Vasavanonda, Sudthida ^a   Han, Lixin ^a   Lin, C Thomas ^a   Hsu, Ann ^a   Kempf, Dale J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINONE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS REPLICATION; DRUG COMBINATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGICAL EXAMINATION;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINONES;

EID: 0035984802     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.7.2249-2253.2002     Document Type: Article

References (17)

1. Multiple drug effect analysis with confidence interval
2. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
3. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates
4. Quantitative analysis of dose effect relationships: The combined effects of multiple drugs or enzyme inhibitors
5. The median-effect principle and the combination index for quantitation of synergism
6. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication
7. The effect of treatment intensification in HIV infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
8. Significance of P-glycoprotein for the pharmacology and clinical use of protease inhibitors
9. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance
10. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
11. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
12. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
13. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV infection: 48-Week results
14. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro
15. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
16. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates
17. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed